DDInter1642 DDInter1608
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , [FDA label]. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) , however, has now been approved for a variety of conditions [FDA label]. On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) .
Rituximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Rituximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Rituximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palifermin
Rituximab {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Rituximab {u} may lead to a major life threatening interaction when taken with {v} Infliximab
Rituximab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Palifermin
Rituximab may lead to a major life threatening interaction when taken with Golimumab
Rituximab may lead to a major life threatening interaction when taken with Infliximab